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Payment (BHP) and Health Care Expenditure (HCE) were more
precise measurements of equity in health care ﬁnance and uti-
lization, respectively. The BHP was deﬁned as the ratio of the
sum of the premium and out-of-pocket spending to disposable
income. We used the 1992–2002 data to examine the following
hypotheses at the individual level, categorized into ﬁve income
quintiles: Hypothesis 1: Equity in BHP and HCE improves after
having the NHI program. Hypothesis 2: Equity in BHP and HCE
deteriorates with recession. We categorized the data into ﬁve
income quintiles. RESULTS: This study conﬁrms the two
hypotheses. NHI can narrow the disparity in medical care equity,
but recession can widen it. We found that the BHP was regres-
sive, while the HCE for the poorest is signiﬁcantly higher than
that for the others. We also found that the recession of 2001 had
a signiﬁcantly greater impact on the poor versus the rich quin-
tile. In conclusion, NHI reform is still an unﬁnished job. CON-
CLUSIONS: The resource allocations need to be rearranged
whenever a recession occurs.
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There is widespread concern over the ability to pay for (“afford-
ability” of) total health care expenditures (THE) rising faster
than gross domestic product (GDP). Current predictions of
future health spending trends suggest, for the U.S. and Germany
alike, that THE growth may exceed GDP growth rates by up to
two-percentage points. OBJECTIVE: To estimate, from a macro-
economic perspective, the extent of future ability to pay, in the
United States and Germany, for THE growth outpacing GDP
growth by two percentage points and its sensitivity to assumed
economic growth rates. METHODS: We assumed the upper
limit of “ability to pay” to be reached once the increase of THE
would fully absorb the growth of GDP, i.e., when non-health
spending would stagnate or commence to decline. Using a math-
ematical model based on this incremental deﬁnition of “afford-
ability”, we conducted one-way and two-way sensitivity analyses
to examine the relationship between “affordable” THE and GDP
growth. RESULTS: Under a base case assumption of real per-
capita GDP growth rates of 1.2 percent per year, both economies
(U.S. and Germany) could afford a two-percentage-point gap
between THE and GDP for the next several decades (United
States: beyond 2050; Germany: beyond 2060). Two-way sensi-
tivity analysis revealed that higher GDP growth rates resulted in
slight increases of this time span only, whereas the time of afford-
able THE growth exhibited high and asymmetric sensitivity to
lower rates of real per-capita GDP growth. CONCLUSION:
Under the assumption of real per-capita GDP growth rates above
one percent annually, societal willingness to pay, not ability to
pay, will determine the extent of future THE growth. Future
funding of health care will be determined by distributive aspects
and the value of health (care), not “affordability”.
PHP12
FACTORS AFFECTING CONSUMER VIEWS REGARDING
GENERIC DRUG SUBSTITUTION PRACTICES: AN EFFECTIVE
TOOL TO MANAGE HEALTH CARE COST
Bhosle MJ, Sansgiry SS
University of Houston, Houston,TX, USA
OBJECTIVES: Consumer opinions are important to increase use
of less expensive generic drugs. The objective of this study was
to examine factors that may affect consumer perceptions regard-
ing generic drug substitution practices. METHODS: Data were
collected from consumers ﬁlling prescriptions at 10 Walgreen
stores situated around Houston (N = 1000) by administering a
survey. Factors such as prior drug purchase behavior and role of
pharmacists were measured using four items on a 5-point scale
where 1 = never and 5 = always. Consumer perception about
generic drugs was measured using a semantic differential scale.
A 5-point Likert scale was used to evaluate their perception
regarding drug substitution practices. Demographic data such as
age, gender, education and income were collected and analyzed
to perform descriptive and correlation analyses. RESULTS: A
total of 505 completed surveys were analyzed. The mean age 
was (42.63 3–4 15.8) years with 90.51% being enrolled in the
health plan. Majority were female (62.02%) and fulltime
employees (61.9%). Respondents had a positive attitude towards
generic drugs (3.84 3–4 0.89) and drug substitution practices (3.74
3–4 0.79). The correlation analysis indicated a positive correlation
between consumers *.115 perception regarding drug substitution
practices and prior use of prescription (r = 0.49, p < 0.05) and
non-prescription drugs (r = 0.28, p < 0.05). Although half of the
participants (54%) indicated that they never refused their phar-
macists for substituting with a generic drug, only 11.20% of the
participants indicated being always asked by their pharmacists
for such substitution. CONCLUSIONS: Consumers’ positive
perceptions towards generic drug and generic drug substitution
practices could help drug management strategies by managed
care organizations to reduce health care costs. Pharmacists may
need to be provided incentives to actively promote generic sub-
stitution to consumers.
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OBJECTIVE: Texas, compared to many other state Medicaid
programs, provides relatively unrestricted coverage of OTC med-
ications that are prescribed by a physician to non-institutional-
ized clients. We conducted a descriptive analysis to investigate
utilization and payment trends for this class of drugs.
METHODS: A retrospective analysis of Texas Medicaid paid
prescription claims for OTC medications dispensed during the
ﬁrst three months of 2003 for Fee-For-Service and Primary Care
Case Management clients was conducted. All OTC products
were included in the analyses, with the exception of insulin prod-
ucts, and syringes. The association of a claim for an OTC med-
ication as a result of an actual physician visit was also assessed.
RESULTS: During the study period, there were a total of
609,185 OTC prescription claims (7.1% of total claims)
accounting for $5.1 million in Texas Medicaid payments (1.1%
of total pharmacy program payments). The average payment per
OTC claim was $8.44. Acetaminophen and oral liquid elec-
trolytes, alone, accounted for 50.4% of all claims and 59.8% of
all payments. Children aged two years or less accounted for
50.1% of all OTC medications dispensed and 49.1% of all OTC
payments. A total of 8.8% of all eligible clients aged 18 and
under had at least one paid OTC claim during January 2003.
Pediatricians, alone, prescribed 50.3% of all OTC medications.
We found that 71.1% of the OTC claims were the result of an
actual physician ofﬁce visit. In addition, 84.3% of pharmacy
visits for OTC claims also had a claim for a prescription-only
